REGEN BIOLOGICS INC - 10-Q Quarterly Report

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2004

( )

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-20805

ReGen Biologics, Inc.

(Exact name of registrant as specified in its charter)


		Delaware		23-2476415
		(State or other jurisdiction of		(I.R.S. Employer
		incorporation or organization)		Identification No.)

		509 Commerce Street,
		1st Floor, East Wing,
		Franklin Lakes, NJ		07417
		(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:

(201) 651-5140

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:
Title of Class

Common Stock $.01 par value per share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (X) No ( )

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ( ) No (X)

The number of outstanding shares of the registrant’s common stock as of August 10, 2004 was 48,249,533.

PART I — Financial Information

Item 1. Financial Statements

REGEN BIOLOGICS, INC.
(A Development Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands, except per share data)


	June 30, 2004			December 31, 2003
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	15,208		$	8,323
Trade receivables		51			11
Receivables from related parties		68			—
Inventory		169			216
Prepaid expenses and other current assets		216			247

Total current assets		15,712			8,797
Property and equipment, net		54			80
Other assets		137			152

Total assets	$	15,903		$	9,029

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	632		$	408
Accounts payable to related parties		18			26
Accrued expenses		446			541
Current portion of capital leases		6			4

Total current liabilities		1,102			979
Pension liability		158			144
Other liabilities		19			19
Long-term portion of capital leases		3			3
Long-term portion of notes payable to related parties, including accrued interest of $1,017 and $958 as of June 30, 2004 and December 31, 2003, respectively		7,060			7,001

Total liabilities		8,342			8,146
Series A redeemable convertible preferred stock, $.01 par value; 30,000,000 shares authorized, liquidation preference of $6,659; and 14,860,969 shares issued and outstanding as of June 30, 2004 and $6,855; and 15,298,351 shares issued and outstanding as of December 31, 2003		6,659			6,855
Series C redeemable convertible preferred stock, $.01 par value; 30,000,000 shares authorized, liquidation preference of $7,227; and 16,128,759 issued and outstanding as of June 30, 2004 and $9,969; and 22,246,153 issued and outstanding as of December 31, 2003		6,194			8,439
Stockholders’ equity (deficit):
Common stock		481			293
Accumulated other comprehensive loss		(58	)		(58	)
Additional paid-in capital		50,092			37,249
Deficit accumulated during development stage		(55,807	)		(51,895	)

Total stockholders’ equity (deficit)		(5,292	)		(14,411	)

Total liabilities and stockholders’ equity (deficit)	$	15,903		$	9,029

See accompanying Notes to Condensed Consolidated Financial Statements.

REGEN BIOLOGICS, INC.
(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in thousands, except per share data)


													Period from
	Three Months Ended June 30,						Six Months Ended June 30 ,						December 21, 1989
													(Inception) to
	2004			2003			2004			2003			June 30, 2004
	(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)
Revenues:
Sales	$	146		$	24		$	241		$	198		$	2,636
Royalties		13			5			25			13			166
Grant and other revenue		—			—			—			—			433

Total revenues		159			29			266			211			3,235
Expenses:
Costs of goods sold		122			25			181			296			3,112
Research and development		919			737			1,704			1,147			29,171
Business development, general and administrative		813			695			1,620			1,251			15,346
Compensation expense associated with stock options and warrants		38			1			157			1			6,499

Total expenses		1,892			1,458			3,662			2,695			54,128
Operating loss		(1,733	)		(1,429	)		(3,396	)		(2,484	)		(50,893	)
Merger cost		—			—			—			—			(515	)
Interest and other income		30			2			39			7			1,273
Rental income		83			107			162			238			1,728
Rent expense		(83	)		(105	)		(161	)		(214	)		(1,592	)
Interest expense		(31	)		(27	)		(60	)		(63	)		(3,019	)
License fees		—			—			—			—			2,050

Net loss	$	(1,734	)	$	(1,452	)	$	(3,416	)	$	(2,516	)	$	(50,968	)

Deemed dividend to Series C Preferred Stockholders upon issuance of Series C Preferred Stock with a beneficial conversion and amortization of related issuance cost		(444	)		—			(496	)		—			(4,839	)

Net loss attributable to common stockholders	$	(2,178	)	$	(1,452	)	$	(3,912	)	$	(2,516	)	$	(55,807	)

Basic and diluted net loss per share attributable to common stockholders	$	(0.05	)	$	(0.05	)	$	(0.11	)	$	(0.09	)	$	(3.01	)

Weighted average number of shares used for calculation of net loss per share		41,003,054			29,070,786			35,162,690			29,070,786			18,540,717

See accompanying Notes to Condensed Consolidated Financial Statements.

ReGen Biologics, Inc.

(A DEVELOPMENT STAGE COMPANY)

Consolidated Statement of Changes in Stockholders’ Equity (Deficit) and
Series A and Series C Redeemable Convertible Preferred Stock

Period from December 21, 1989 (inception) to June 30, 2004 (unaudited)

(Dollars in thousands, per share data)

Stockholders Equity (Deficit)

Series A Redeemable

Series C Redeemable

Series A - F

Series B

Convertible Preferred

Convertible

Convertible Preferred

Stock

Preferred Stock

Stock

Common Stock

Share

Amount

Share

Amount

Shares

Amount

Shares

Amount

Shares

Amount

Issuance of common stock at $0.03127 per share for net assets contributed by founders in May 1990

–

1,400,000

Issuance of common stock at $0.005 per share for cash in November 1991

–

700,000

–

Issuance of Series A convertible preferred stock at $1.00 per share for cash in April 1991, net of offering costs of $44

725,000

–

Issuance of Series B convertible preferred stock at $3.00 per share for cash and in exchange for notes payable in January, March, May, and July 1992, net of offering costs of $29

1,226,338

–

Net loss from inception (December 21, 1989) through December 31, 1992

–

Balance at December 31, 1992

1,951,338

2,100,000

Issuance of Series C convertible preferred stock at $4.50 per share for cash in December 1993, net of offering costs of $29

550,552

–

Exercise of common stock options at $0.30 per share for cash in February 1993

–

200

–

Issuance of common stock at $0.30 per share in 1993 in exchange for services to a consultant

–

5,000

–

Net loss

–

Balance at December 31, 1993

2,501,890

2,105,200

Net loss

–

Balance at December 31, 1994

2,501,890

2,105,200

Net loss

–

Balance at December 31, 1995

2,501,890

2,105,200

[Additional columns below]

[Continued from above table, first column(s) repeated]


	Stockholders Equity (Deficit)
					Deficit
	Additional		Deferred		Accumulated			Accumulated Other	Total Stockholders’
	Paid In		Stock		During Development			Comprehensive	Equity
	Capital		Compensation		Stage			Loss	(Deficit)
Issuance of common stock at $0.03127 per share for net assets contributed by founders in May 1990	$	44	$	–	$	–			$	45
Issuance of common stock at $0.005 per share for cash in November 1991		3		–		–				3
Issuance of Series A convertible preferred stock at $1.00 per share for cash in April 1991, net of offering costs of $44		681		–		–				682
Issuance of Series B convertible preferred stock at $3.00 per share for cash and in exchange for notes payable in January, March, May, and July 1992, net of offering costs of $29		3,650		–		–				3,650
Net loss from inception (December 21, 1989) through December 31, 1992		–		–		(2,476	)			(2,476	)
Balance at December 31, 1992		4,378		–		(2,476	)			1,904
Issuance of Series C convertible preferred stock at $4.50 per share for cash in December 1993, net of offering costs of $29		2,448		–		–				2,448
Exercise of common stock options at $0.30 per share for cash in February 1993		1		–		–				1
Issuance of common stock at $0.30 per share in 1993 in exchange for services to a consultant		1		–		–				1
Net loss		–		–		(1,342	)			(1,342	)
Balance at December 31, 1993		6,828		–		(3,818	)			3,012
Net loss		–		–		(1,463	)			(1,463	)
Balance at December 31, 1994		6,828		–		(5,281	)			1,549
Net loss		–		–		(1,959	)			(1,959	)
Balance at December 31, 1995	$	6,828		–	$	(7,240	)		$	(410	)

See accompanying Notes to Condensed Consolidated Financial Statements

ReGen Biologics, Inc.

(A DEVELOPMENT STAGE COMPANY)

Consolidated Statement of Changes in Stockholders’ Equity (Deficit) and Series
A and Series C Redeemable Convertible Preferred Stock

Period from December 21, 1989 (inception) to June 30, 2004 (unaudited)

(Dollars in thousands, except per share data)

Stockholders’ Equity (Deficit)

Series A

Series C

Series A - F

Series B

Redeemable Convertible

Convertible

Convertible Preferred

Preferred Stock

Stock

Common Stock

Shares

Amount

Shares

Amount

Shares

Amount

Shares

Amount

Shares

Amount

Balance at December 31, 1995 (carried forward)

2,501,890

2,105,200

Issuance of Series D convertible preferred stock at $7.25 per share for cash in March and April 1996, net of offering costs of $536

1,191,321

–

Exercise of common stock options at $0.10, $0.30, and $0.45 per share in August and October 1996

–

163,333

–

Net loss

–

Balance at December 31, 1996

3,693,211

2,268,533

Issuance of Series E convertible preferred stock at $7.25 per share for cash in August and September 1997, net of offering costs of $53

335,314

–

Exercise of common stock options at $0.10, $0.30, and $0.45 per share in April, August, and September 1997

–

32,111

–

Net loss

–

Balance at December 31, 1997

4,028,525

2,300,644

Exercise of common stock options at $0.10, $0.20, $1.27, and $1.45 per share in May, July, November and December 1998, respectively

–

159,879

–

Compensation expense associated with stock option modifications

–

Net loss

–

Balance at December 31, 1998

4,028,525

2,460,523

Exercise of common stock options at $.725 and $1.45 per share in April, June and August 1999

–

42,396

–

Issuance of Series F convertible preferred stock at $8.73 per share for cash

453,310

–

Compensation expense associated with stock option grants

–

Net loss

–

Balance at December 31, 1999

4,481,835

2,502,919

[Additional columns below]

[Continued from above table, first column(s) repeated]


	Stockholders’ Equity (Deficit)
						Deficit
	Additional					Accumulated			Accumulated Other	Total Stockholders’
	Paid In		Deferred Stock			During Development			Comprehensive	Equity
	Capital		Compensation			Stage			Loss	(Deficit)
Balance at December 31, 1995 (carried forward)	$	6,828	$	–		$	(7,240	)		$	(410	)
Issuance of Series D convertible preferred stock at $7.25 per share for cash in March and April 1996, net of offering costs of $536		8,101		–			–				8,101
Exercise of common stock options at $0.10, $0.30, and $0.45 per share in August and October 1996		43		–			–				43
Net loss		–		–			(1,931	)			(1,931	)
Balance at December 31, 1996		14,972		–			(9,171	)			5,803
Issuance of Series E convertible preferred stock at $7.25 per share for cash in August and September 1997, net of offering costs of $53		2,378		–			–				2,378
Exercise of common stock options at $0.10, $0.30, and $0.45 per share in April, August, and September 1997		5		–			–				5
Net loss		–		–			(3,868	)			(3,868	)
Balance at December 31, 1997		17,355		–			(13,039	)			4,318
Exercise of common stock options at $0.10, $0.20, $1.27, and $1.45 per share in May, July, November and December 1998, respectively		108		–			–				108
Compensation expense associated with stock option modifications		56		–			–				56
Net loss		–		–			(3,815	)			(3,815	)
Balance at December 31, 1998		17,519		–			(16,854	)			667
Exercise of common stock options at $.725 and $1.45 per share in April, June and August 1999		32		–			–				32
Issuance of Series F convertible preferred stock at $8.73 per share for cash		3,956		–			–				3,956
Compensation expense associated with stock option grants		3,436		(3,247	)		–				189
Net loss		–		–			(5,458	)			(5,458	)
Balance at December 31, 1999	$	24,943	$	(3,247	)	$	(22,312	)		$	(614	)

See accompanying Notes to Condensed Consolidated Financial Statements

ReGen Biologics, Inc.
(A DEVELOPMENT STAGE COMPANY)
Consolidated Statement of Changes in Stockholders’ Equity (Deficit) and Series
A and Series C Redeemable Convertible Preferred Stock

Period from December 21, 1989 (inception) to June 30, 2004 (unaudited)

(Dollars in thousands, except per share data)

Stockholders’ Equity (Deficit)

Series A Redeemable

Series C Redeemable

Convertible

Convertible Preferred

Series A – F Convertible

Series B Convertible

Preferred Stock

Series C

Preferred Stock

Shares

Amount

Shares

Amount

Shares

Amount

Shares

Amount

Balance at December 31, 1999 (carried forward)

4,481,835

Compensation expense associated with stock option grants in prior year

–

Compensation expense associated with stock option grants in current year

–

Stock options cancelled during 2000

–

Net loss

–

Balance at December 31, 2000

4,481,835

Exercise of common stock options at $.10 per share in 2001

–

Exercise of common stock options at $1.45 per share in 2001

–

Compensation expense associated with stock option grants in prior years

–

Compensation expense associated with stock option grants in current year

–

Stock options cancelled during 2001

–

Deferred stock compensation associated with stock option grants to non-employees in 2001

–

Net loss

–

Balance at December 31, 2001

4,481,835

[Additional columns below]

[Continued from above table, first column(s) repeated]


	Stockholders’ Equity (Deficit)
	Common Stock										Deficit Accumulated			Accumulated Other
					Additional Paid In			Deferred Stock			During Development			Comprehensive	Total Stockholders’ Equity
	Shares		Amount		Capital			Compensation			Stage			Loss	(Deficit)
Balance at December 31, 1999 (carried forward)		2,502,919	$	1	$	24,943		$	(3,247	)	$	(22,312	)		$	(614	)
Compensation expense associated with stock option grants in prior year		–		–		–			738			–				738
Compensation expense associated with stock option grants in current year		–		–		2,124			(1,642	)		–				482
Stock options cancelled during 2000		–		–		(1,089	)		1,089			–				–
Net loss		–		–		–			–			(5,229	)			(5,229	)
Balance at December 31, 2000		2,502,919		1		25,978			(3,062	)		(27,541	)			(4,623	)
Exercise of common stock options at $.10 per share in 2001		25,000		–		3			–			–				3
Exercise of common stock options at $1.45 per share in 2001		125		–		–			–			–				–
Compensation expense associated with stock option grants in prior years		–		–		–			935			–				935
Compensation expense associated with stock option grants in current year		–		–		1,010			(833	)		–				177
Stock options cancelled during 2001		–		–		(161	)		161			–				–
Deferred stock compensation associated with stock option grants to non-employees in 2001		–		–		228			(131	)		–				97
Net loss		–		–		–			–			(4,330	)			(4,330	)
Balance at December 31, 2001		2,528,044	$	1	$	27,058		$	(2,930	)	$	(31,871	)		$	(7,741	)

See accompanying Notes to Condensed Consolidated Financial Statements


										Stockholders’ Equity (Deficit)
	Series A				Series C					Series A - F
	Redeemable Convertible				Redeemable Convertible					Convertible						Series B
	Preferred Stock				Preferred Stock					Preferred Stock						Convertible Preferred Stock
	Shares		Amount		Shares		Amount			Shares			Amount			Shares			Amount
Balance at December 31, 2001 (carried forward)											4,481,835		$	1
Issuance of Common Stock
Issuance of Convertible Preferred Stock for cash and conversion of bridge financing net of issuance costs of $138											5,564,047			1
Deferred stock compensation associated with stock option grants in 2002
Compensation expense associated with stock options outstanding
Effect of reverse merger and recapitalization:
Valuation of warrants associated with bridge financing
Valuation of beneficial conversion associated with bridge financing
Compensation expense associated with stock options outstanding recognized as a result of the reverse merger
Conversion of convertible preferred shares to Redeemable Convertible Preferred Series A at liquidation / redemption value		15,298,351	$	6,855							(5,564,047	)		(1	)
Conversion of convertible preferred shares to Common Stock and Series B Preferred Shares											(4,481,835	)		(1	)		12,025,656		$	120
Conversion of Subsidiary Common Stock into Company Common Stock and Series B Preferred Shares:
Elimination of Subsidiary Common Stock
Issuance of Company Common Stock
Company Common Stock and related equity held by existing shareholders (net of 18,115 shares held treasury)
Conversion of Convertible Preferred Series B Stock to Company Common Stock																	(12,025,656	)		(120	)
Minimum Pension Liability
Net loss
Other Comprehensive Loss
Balance at December 31, 2002		15,298,351		6,855							—			—			—			—
Compensation expense associated with stock options outstanding
Issuance of Redeemable Convertible Preferred Series C Stock, net of issuance costs of $612, which include the issuance of non-cash consideration in the form of warrants						22,246,153	$	9,357
Issuance of Common Stock warrants to Series C Stockholders								(969	)
Valuation of beneficial conversion associated with Series C Stock financing								(4,292	)
Accretion of beneficial conversion associated with Series C Stock financing								4,292
Issuance of Common Stock – warrants exercised
Accretion of Series C Stock issuance cost								51
Net loss and comprehensive loss
Balance at December 31, 2003		15,298,351	$	6,855		22,246,153	$	8,439			—		$	—			—		$	—

[Additional columns below]

[Continued from above table, first column(s) repeated]


	Stockholders’ Equity (Deficit)
													Deficit
													Accumulated			Accumulated
	Common Stock						Additional Paid In			Deferred Stock			During Development			Other Comprehensive			Total Stockholders’
	Shares			Amount			Capital			Compensation			Stage			Loss			Equity (Deficit)
Balance at December 31, 2001 (carried forward)		2,528,044		$	1		$	27,058		$	(2,930	)	$	(31,871	)				$	(7,741	)
Issuance of Common Stock		301,930			1			104												105
Issuance of Convertible Preferred Stock for cash and conversion of bridge financing net of issuance costs of $138								6,716												6,717
Deferred stock compensation associated with stock option grants in 2002								370			(370	)
Compensation expense associated with stock options outstanding											452									452
Effect of reverse merger and recapitalization:
Valuation of warrants associated with bridge financing								657												657
Valuation of beneficial conversion associated with bridge financing								843												843
Compensation expense associated with stock options outstanding recognized as a result of the reverse merger											2,848									2,848
Conversion of convertible preferred shares to Redeemable Convertible Preferred Series A at liquidation / redemption value								(6,854	)											(6,855	)
Conversion of convertible preferred shares to Common Stock and Series B Preferred Shares		297,146			3			(122	)
Conversion of Subsidiary Common Stock into Company Common Stock and Series B Preferred Shares:
Elimination of Subsidiary Common Stock		(2,829,974	)		(1	)		1
Issuance of Company Common Stock		7,781,018			78			(78	)
Company Common Stock and related equity held by existing shareholders (net of 18,115 shares held treasury)		8,966,966			89			2,678												2,767
Conversion of Convertible Preferred Series B Stock to Company Common Stock		12,025,656			120
Minimum Pension Liability																$	(58	)		(58	)
Net loss														(9,951	)					(9,951	)
Other Comprehensive Loss																				(10,009	)
Balance at December 31, 2002		29,070,786			291			31,373			—			(41,822	)		(58	)		(10,216	)
Compensation expense associated with stock options outstanding								405												405
Issuance of Redeemable Convertible Preferred Series C Stock, net of issuance costs of $612, which include the issuance of non-cash consideration in the form of warrants								97												97
Issuance of Common Stock warrants to Series C Stockholders								969												969
Valuation of beneficial conversion associated with Series C Stock financing								4,292												4,292
Accretion of beneficial conversion associated with Series C Stock financing														(4,292	)					(4,292	)
Issuance of Common Stock – warrants exercised		230,000			2			113												115
Accretion of Series C Stock issuance cost														(51	)					(51	)
Net loss and comprehensive loss														(5,730	)					(5,730	)
Balance at December 31, 2003		29,300,786		$	293		$	37,249		$	—		$	(51,895	)	$	(58	)	$	(14,411	)

See accompanying Notes to Condensed Consolidated Financial Statements.

ReGen Biologics, Inc.
(A DEVELOPMENT STAGE COMPANY)
Consolidated Statement of Changes in Stockholders’ Equity (Deficit) and Series
A and Series C Redeemable Convertible Preferred Stock

Period from December 21, 1989 (inception) to June 30, 2004 (unaudited)
(Dollars in thousands, except per share data)


													Stockholders’ Equity (Deficit)
	Series A						Series C						Series A - F
	Redeemable Convertible						Redeemable Convertible						Convertible				Series B
	Preferred Stock						Preferred Stock						Preferred Stock				Convertible Preferred Stock
	Shares			Amount			Shares			Amount			Shares		Amount		Shares		Amount
Balance at December 31, 2003		15,298,351		$	6,855			22,246,153		$	8,439			—	$	—		—	$	—
Compensation expense associated with stock options outstanding
Accretion of Series C Stock issuance cost											100
Recognition of Series C Stock issuance cost upon conversion											396
Issuance of Common Stock – warrants exercised net of 8,901 shares held treasury
Issuance of Common Stock – options exercised
Issuance of Common Stock – common stock offering
Conversion of Series A Stock to Common Stock		(437,382	)		(196	)
Conversion of Series C Stock to Common Stock								(6,117,394	)		(2,741	)
Net loss and comprehensive loss
Balance at June 30, 2004 (unaudited)		14,860,969		$	6,659			16,128,759		$	6,194			—	$	—		—	$	—

[Additional columns below]

[Continued from above table, first column(s) repeated]


	Stockholders’ Equity (Deficit)
									Deficit
									Accumulated			Accumulated
	Common Stock				Additional				During			Other			Total
					Paid In		Deferred Stock		Development			Comprehensive			Stockholders’
	Shares		Amount		Capital		Compensation		Stage			Loss			Equity (Deficit)
Balance at December 31, 2003		29,300,786	$	293	$	37,249	$	—	$	(51,895	)	$	(58	)	$	(14,411	)
Compensation expense associated with stock options outstanding						184										184
Accretion of Series C Stock issuance cost										(100	)					(100	)
Recognition of Series C Stock issuance cost upon conversion										(396	)					(396	)
Issuance of Common Stock – warrants exercised net of 8,901 shares held treasury		79,211		1		30										31
Issuance of Common Stock – options exercised		80,000		1		12										13
Issuance of Common Stock – common stock offering		12,074,595		121		9,745										9,866
Conversion of Series A Stock to Common Stock		437,382		4		192										196
Conversion of Series C Stock to Common Stock		6,117,394		61		2,680										2,741
Net loss and comprehensive loss										(3,416	)					(3,416	)
Balance at June 30, 2004 (unaudited)		48,089,368	$	481	$	50,092	$	—	$	(55,807	)	$	(58	)	$	(5,292	)

See accompanying Notes to Condensed Consolidated Financial Statements.

REGEN BIOLOGICS, INC.
(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollar in thousands)


							Period from
	Six Months Ended June 30,						December 21, 1989 (Inception) to
	2004			2003			June 30, 2004
	(unaudited)			(unaudited)			(unaudited)
Operating Activities
Net loss	$	(3,416	)	$	(2,516	)	$	(50,968	)
Adjustments to reconcile net loss to net cash used in operating activities:
Compensation expense associated with stock options		157			1			6,501
Amortization of debt discount for warrant and beneficial conversion feature		—			—			1,500
Non-cash interest expense		59			63			1,213
Depreciation and amortization		40			63			2,166
Loss on disposal of property and equipment		—			—			9
Changes in operating assets and liabilities:
Other current assets and receivables		(49	)		58			(214	)
Inventory		47			(10	)		(169	)
Other assets		15			14			(87	)
Accounts payable and accrued expenses		121			192			785
Other liabilities		14			(25	)		33

Net cash used in operating activities		(3,012	)		(2,160	)		(39,231	)

Investing Activities
Purchases of property and equipment		(10	)		(20	)		(1,993	)
Changes in short-term investments		—			2,184			2,945

Net cash provided by (used in) investing activities		(10	)		2,164			952

Financing Activities
Issuance of common stock to founders for contributed patents		—			—			42
Issuance of Series B preferred stock upon conversion of interest payable		—			—			6
Reduction in payable to stockholder		—			—			(76	)
Proceeds from issuance of convertible preferred stock, net of offering costs paid in cash		—			—			34,221
Proceeds from issuance of common stock, net of offering costs paid in cash		9,909			—			10,325
Repayment of capital lease obligations		(2	)		(4	)		(119	)
Proceeds from notes payable		—			—			11,410
Payments on notes payable		—			—			(2,323	)

Net cash provided by (used in) financing activities		9,907			(4	)		53,486

Net increase (decrease) in cash		6,885			—			15,207
Cash at beginning of period		8,323			1			1

Cash at end of period	$	15,208		$	1		$	15,208

Supplemental Disclosure of Cash Flow Information
Non-cash disclosure:
Issuance of Series B convertible preferred stock upon conversion of notes payable	$	—		$	—		$	300
Equipment purchased pursuant to capital leases		4			—			128
Cancellation of stock options associated with deferred stock compensation		—			—			1,250
Net assets assumed in merger		—			—			2,733
Conversion of bridge financing to equity		—			—			2,860
Beneficial Conversion of Series C Stock		—			—			4,292
Warrants associated with Series C Stock		—			—			969
Warrants associated with Series C Stock private placement agent fee		—			—			97
Conversion of Series A Stock		196			—			196
Warrants exercised, cashless transaction		10			—			10
Conversion of Series C Stock		2,741			—			2,741
Cash disclosure:
Cash paid for interest		1			—			315

See accompanying Notes to Condensed Consolidated Financial Statements.

REGEN BIOLOGICS, INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except per share data)

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

On June 21, 2002, ReGen Biologics, Inc (“ReGen” or the “Company”) acquired RBio, Inc., formerly named ReGen Biologics, Inc. The acquisition was recorded for accounting purposes as a reverse merger and recapitalization. For purposes of this Form 10-Q, the historical financial statements of RBio, Inc., including related notes, have replaced the prior historical financial statements of the Company.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals) necessary to present fairly the financial position and the results of operations for the interim periods.

ReGen will continue to require additional capital to further develop its products and further develop sales and distribution channels for its products around the world. Accordingly, the Company is still considered a development stage enterprise. Management believes that ReGen will emerge from the development stage when the Collagen Meniscus Implant, or CMI, product is available for sale in the U.S. or sales of all of its products have reached a volume that will provide for positive gross margins.

For further information, refer to the consolidated financial statements and notes included in ReGen’s Annual Report on Form 10-K/A for the year ended December 31, 2003.

ReGen currently operates in one business segment that develops and manufactures tissue growth and repair products for unmet markets in both the U.S. and globally. ReGen is managed and operated as one business segment. Accordingly, ReGen does not prepare financial information for separate product areas and does not have separate reportable segments as defined by Statement of Financial Accounting Standards (SFAS) No. 131, Disclosure about Segments of an Enterprise and Related Information.

Concentrations of Risk

The Company currently has two principal customers, which market and sell the Company’s two current products. Customer A has the license to sell the SharpShooter product. Customer B, which is also a shareholder of the Company, has a non-exclusive license to sell the CMI product outside of the United States and a license to sell the SharpShooter product in a limited manner in connection with the sale of the CMI. Concentrations of receivables and revenues by customer are as follows:


	Three Months Ended June 30,						Six Months Ended June 30,						December 31,
	2004			2003			2004			2003			2003
Accounts receivable:
Customer A		43	%		83	%		43	%		83	%		100	%
Customer B		57	%		17	%		57	%		17	%		0	%
Sales revenues:
Customer A		46	%		5	%		66	%		24	%		23	%
Customer B		54	%		95	%		34	%		76	%		77	%
Royalties:
Customer A		100	%		100	%		100	%		100	%		100	%

In several cases the Company relies on a single vendor to supply critical materials or components. All of these materials and components can currently be obtained by alternative suppliers, subject to the time and other resources required to initiate new vendor relationships.

Adoption of New Accounting Pronouncements

In January 2003, the FASB issued Interpretation No. 46 (FIN 46), Consolidation of Variable Interest Entities. Interpretation No. 46 requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity’s activities or is entitled to receive a majority of the entity’s residual returns or both. Previously, entities were generally consolidated by a company that had a controlling financial interest through ownership of a majority voting interest in the entity. In December 2003, the FASB issued FIN 46 (revised December 2003), Consolidation of Variable Interest Entities, (FIN 46R) to clarify some of the provisions of FIN 46. For the year ended December 31, 2003, the Company was required to apply the provisions of FIN 46 that relate to special purpose entities (SPEs) created prior to February 1, 2003. Adoption of these provisions did not have a material impact on the Company’s financial statements. For the quarter ended March 31, 2004, the Company is required to adopt the provisions related to non-SPEs created prior to February 1, 2003, and the provisions related to all entities, regardless of whether an SPE, that were created subsequent to January 31, 2003. Adoption of these provisions did not have a material impact on the Company’s financial statements.

In December 2003, the FASB issued FASB Statement No. 132 (revised 2003), Employers’ Disclosures about Pensions and Other Postretirement Benefits. The revised standard requires new disclosures in addition to those required by the original standard about the assets, obligations, cash flows and net periodic benefit cost of defined benefit pension plans and other defined benefit postretirement plans. As revised, SFAS No. 132 is effective for financial statements with fiscal years ending after December 15, 2003. The interim-period disclosures required by this standard are effective for interim periods beginning after December 15, 2003. See “Defined Benefit Plan” for newly required interim disclosures.

Reclassifications

Certain prior year and inception to June 30, 2004 balances have been reclassified to conform to the current period’s presentation.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with a maturity of 90 days or less at the date of acquisition to be cash equivalents and as such has classified cash held in a money market account and sweep account as cash equivalents. The Company held cash equivalents of $14,471 and $8,091 in a money market account and $737 and $232 in a sweep account as of June 30, 2004 and December 31, 2003, respectively.

Inventories

Inventories are valued at the lower of actual cost or market, using the first-in, first-out (FIFO) method. Work in process is calculated by estimating the number of units that will be successfully converted to finished goods, based upon a build-up in the stage of completion using estimated labor inputs for each stage and historical yields reduced by estimated usage for quality control testing and for research and development.

Inventory consists of the following:


	June 30,		December 31,
	2004		2003
	(In thousands)
Raw material	$	23	$	29
Work in process		51		16
Finished goods		95		171

	$	169	$	216

Inventory was adjusted down $107 and $62 during the periods ended June 30, 2004 and December 31, 2003, respectively, to reflect values at the lower of cost or market. At June 30, 2004, 38% of the units in inventory are valued at below the Company’s cost. Due to a high degree of fixed costs in the production process, and the early stage of market acceptance for the Company’s products, current sales and production volumes are not adequate to provide for per unit costs that are lower than the current market prices.

Accrued Expenses

Accrued expenses consist of the following:


	June 30,		December 31,
	2004		2003
	(In thousands)
Accrued professional fees	$	298	$	190
Accrued officer compensation		—		178
Accrued printing cost		25		26
Accrued common stock registration cost		55		75
Accrued vacation		37		22
Other accrued cost		31		50

	$	446	$	541

Defined Benefit Plan

Prior to the reverse merger and recapitalization, the Company sponsored a defined benefit pension plan (“Pension Plan”) covering all former employees of National Health Advisors, a subsidiary of the Company acquired in 1997. The Pension Plan was amended to freeze benefit accruals and the entry of new participants effective October 31, 1997. The sale of the Company’s APACHE business in 2001 resulted in the termination of all remaining participants in the Pension Plan.

The Company previously disclosed in its financial statements for the year ended December 31, 2003, that it did not expect to make contributions to the plan during 2004 and as of June 30, 2004 no contributions have been made. Pension expense during the three month periods ended June 30, 2004 and 2003 was not material.

Stock Based Compensation

The Company has adopted the disclosure only provisions of SFAS No. 123. Accordingly, if the exercise price of the Company’s employee stock options equals or exceeds the estimated fair value of the underlying stock on the date of grant, no compensation expense is generally recognized.

Had compensation costs for the Company’s stock options been determined based on SFAS No. 123 as amended by SFAS No. 148, the Company’s net loss attributable to common stockholders and net loss per share attributable to common stockholders would have been as follows (dollars in thousands, except per share data):


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2004			2003			2004			2003
Net loss attributable to common stockholders, as reported	$	(2,178	)	$	(1,452	)	$	(3,912	)	$	(2,516	)
Add: Total stock-based employee compensation expense as reported under intrinsic value method (APB No 25) for all awards, net of related tax effects		32			—			145			—
Deduct: Total stock-based employee compensation expense determined under fair value based method (SFAS No. 123) for all awards, net of related tax effects		(166	)		(46	)		(419	)		(92	)

Pro forma net loss attributable to common stockholders	$	(2,312	)	$	(1,498	)	$	(4,186	)	$	(2,608	)

Net loss per share attributable to common stockholders:
Basic and diluted — as reported	$	(0.05	)	$	(0.05	)	$	(0.11	)	$	(0.09	)
Basic and diluted — pro forma	$	(0.06	)	$	(0.05	)	$	(0.12	)	$	(0.09	)
Shares		41,003,054			29,070,786			35,162,690			29,070,786

Rental Activities

The Company subleases space in one of its facilities to an unrelated third party. Rental income and expense associated with this sublease are recorded below operating loss. Rental expense includes an allocation of building related expenses based on the ratio of subleased space to total space.

(2) RELATED PARTY TRANSACTIONS

The Company has a cost reimbursement agreement with a shareholder of the Company. For the periods ended June 30, 2004 and December 31, 2003, the Company is entitled to, and recorded as a reduction of business development expenses, reimbursement of approximately $10 and $90, respectively.

For the three months ended June 30, 2004 and June 30, 2003, 54% and 95%, respectively of the Company’s revenues were from sales to Customer B, a related party. For the six months ended June 30, 2004 and June 30, 2003, 34% and 76%, respectively of the Company’s revenues were from sales to Customer B, a related party.

At June 30, 2004 and December 31, 2003, approximately $18 and $26 of accounts payable were due to related parties for services or reimbursed expenses including officers or directors who are also shareholders. The Company has paid $39 and $107 to the afore mentioned related parties during the six months ended June 30, 2004 and the year ended December 31, 2003, respectively.

During the second quarter 2004 the Company made a donation of approximately $8 to the Steadman Hawkins Foundation for orthopedic research. Dr. Steadman, a director and shareholder of the Company is the director of the Foundation.

(3) FINANCINGS AND CAPITAL TRANSACTIONS

The Series C Stock and Series A Stock are subject to Registration Rights Agreements entered into as of September 23, 2003 and September 30, 2003 whereby the holders of such shares have, in certain circumstances, the right to require the Company to register the common shares into which the Series C Stock and the Series A Stock is convertible. ReGen has received notice from certain holders of the Series C Stock and Series A Stock, representing 35,549,814 shares, requesting that ReGen register such shares pursuant to the terms of the Registration Rights Agreements.

In the second quarter of 2004, holders of 437,382 shares of Series A Redeemable Convertible Preferred Stock and 6,117,394 shares of Series C Redeemable Convertible Preferred Stock exercised their right to convert their shares to an equal number of shares of common stock. As a result of this conversion, $396 of unamortized issuance cost associated with the Series C Stock was immediately recognized as a deemed dividend to preferred stockholders for purposes of determining net loss attributable to common stockholders. The Common Stock issued upon conversion is included in the shares for which ReGen has received notice requesting registration.

On July 14, 2004, the Company filed a preliminary registration statement (the “Registration Statement”) with the SEC on Form S-1 for registration of 47,624,409 shares of common stock. The shares being registered include common shares registered pursuant to the Registration Rights Agreements (issuable upon the conversion of certain shares of Series A Stock and Series C Stock) and the shares issued in the April Financing. The Registration Statement was declared effective with the SEC on July 23, 2004.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (dollars in thousands, except per share data and per unit data)

On June 21, 2002, ReGen Biologics, Inc (“ReGen”) acquired RBio, Inc., formerly named ReGen Biologics, Inc. The acquisition was recorded for accounting purposes as a reverse merger and recapitalization. For purposes of this filing, the historical financial statements of RBio, Inc. including related notes have replaced the prior historical financial statements of ReGen.

The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this Form 10-Q. This section of the Form 10-Q contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations and intentions. We use words such as “anticipate,” “believe,” “expect,” “future” and “intend” and similar expressions to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-Q.

Business

We are a leading orthopedic products company that develops and manufactures tissue growth and repair products for unmet markets in both the U.S. and globally. Our primary product, the Collagen Meniscus Implant, or CMI, is an implant designed to facilitate growth of new tissue to replace removed or missing meniscus tissue in the human knee. A damaged meniscus is frequently treated with an arthroscopic surgical procedure known as a partial meniscectomy. During this procedure, surgeons remove damaged meniscus tissue leaving less meniscus tissue to support the knee and protect the patient from further degeneration or injury. The CMI represents the only product of which we are aware with the potential to facilitate the growth of new tissue in the space created when meniscus tissue is removed through a partial meniscectomy procedure. As indicated from the preliminary results of our clinical studies, the greatest benefits to the patient from implantation of the CMI are seen in the patients who have undergone prior treatment to their meniscus, and include:

• Substantial growth of new tissue in the meniscus, which does not otherwise re-grow after removal in a partial meniscectomy;

• Significantly greater return to a more active lifestyle than those patients’ receiving only a partial meniscectomy; and

• A highly correlated relationship between the patients pain and function, and their degree of return to pre-injury activity, e.g. CMI patients experience an approximately equal level of pain as do the patients in the control group who received only a partial meniscectomy, but do so at a significantly higher return to pre-injury activity levels.

In November 2002, ReGen completed the required enrollment and related surgical procedures for its CMI clinical trial in the U.S. At the request of surgeons participating in the trial, additional patients were enrolled and surgeries completed by early 2003. All patients included in the trial are expected to complete two years of follow-up prior to ReGen’s submission of the results in its PMA to the FDA. ReGen expects the last of these two-year clinical follow-up exams will be completed by early 2005, with submission of the completed PMA to the FDA shortly thereafter. The process of review by the FDA is uncertain, but ReGen expects that the FDA Orthopedic Panel will issue its recommendation to the FDA in late 2005 or early 2006, with a final decision from the FDA thereafter. Should the FDA approve the CMI for sale in the U.S., sales of the CMI in the U.S. are not expected to occur until, at the earliest, late 2006.

The FDA has not yet approved the CMI and there is no guarantee that we will obtain such approval. If we were to obtain FDA approval, we believe the following trends may be relevant to the performance of the Company. The number of partial meniscectomy procedures is expected to grow by approximately 5% per year for the foreseeable future due to the aging population, the growing proportion of “weekend warriors” and the lack of viable alternatives. The number of patients that would be eligible for a medial CMI implant in the U.S., if the CMI were approved by the FDA, is expected to increase to over 40% of all partial meniscectomy procedures, or approximately 476,000 patients, by 2010. We estimate that, based on the expected average sales price of the CMI in the U.S. if the CMI had been approved by the FDA, the U.S. market for the CMI in 2002 would have been approximately $850 million, and is expected to increase to approximately $1.7 billion by 2010 if the CMI is approved by the FDA. This estimate is based on an assumed average reimbursed sales price of $3,500 for the CMI, and does not include surgeon and other facility costs. Sales of the CMI in the U.S. will not occur until it has been approved for sale in the U.S. by the FDA.

The CMI is currently cleared for sale in Europe, Australia and Chile. The CMI is distributed outside the U.S. on a non-exclusive basis by the Centerpulse unit (“Centerpulse”) of Zimmer Holdings, Inc. (NYSE: ZMH) (“Zimmer”).

We also sell the SharpShooter Tissue Repair System, or SharpShooter, a suturing device used to facilitate the surgical implantation of the CMI, as well as to perform other similar arthroscopic meniscal repair procedures. The SharpShooter is currently marketed through a worldwide distribution agreement with Linvatec Corporation (Linvatec), a subsidiary of ConMed (NASDAQ: CNMD). The SharpShooter is cleared for sale in the U.S., Europe, Canada, Australia, Chile and Japan.

In general, we have seen positive reception to the CMI by surgeons and patients in Europe. The CMI is approved for sale in most European countries and Australia, but application for reimbursement approval in certain countries, including Germany, the largest European country, is still underway. The primary business of Centerpulse, the Company’s non-exclusive distribution partner in Europe, is the development, production and marketing of joint replacement products for the knee, hip and other joints. We do not believe that Centerpulse has committed the necessary resources to building a marketing and sales initiative for sports medicine products in general or the CMI in particular. In August 2003, Centerpulse agreed to be acquired by Zimmer, and on October 2, 2003 Zimmer announced the completion of its exchange offers. The acquisition by Zimmer resulted in beneficial ownership by Zimmer of 98.7% of Centerpulse’s issued shares. We believe that the ongoing acquisition and business integration-related activities that affected Centerpulse throughout 2003 were disruptive to the focus of its limited resources on building a sports medicine marketing business in general, and on selling the CMI in particular. We believe this trend will continue in 2004.

In 2003 Centerpulse was obligated to sell a minimum of 800 CMIs. On February 5, 2004 Centerpulse delivered its final sales report for the calendar year ended December 31, 2003. This report indicated that Centerpulse failed to meet the minimum sales requirements. According to the terms of the distribution agreement with Centerpulse, we had 45 calendar days from receipt of the final sales report to exercise the options provided to us in the agreement. We have elected to amend the distribution agreement to make the distribution rights to the CMI held by Centerpulse non-exclusive. Pursuant to the terms of the distribution agreement, this election took effect on April 17, 2004, 30 days from the date of Centerpulse’s receipt of our notice.

Our current strategy is to focus on the following initiatives:

• Obtaining FDA approval of the CMI;

• Developing our distribution and marketing capabilities for the CMI both in the U.S. and throughout certain other countries;

• Launching the CMI in the U.S.; and

• Conducting further research on select product opportunities within our research and development pipeline to determine whether to pursue further development of these opportunities.

Our long-term strategy is to capitalize on our proven collagen scaffold technology by continuing to design, develop, manufacture, and market our own products, as well as partner with key market leaders to develop and market products in other targeted therapeutic areas.

Our Core Technology

Our core technology focuses on guided tissue generation. That is, if the body is provided with a suitable environment for cellular ingrowth, the body has the ability to use its own cell structures to grow new tissue. We have developed a proprietary type I bovine collagen scaffold material that uses the body’s own cells to grow new tissue. The various tissue matrix engineering processes used in the design of this scaffold are the basis of our tissue growth technology and product offerings. Our proprietary processes are capable of producing implants with the various physical properties required for remodeling each specific target tissue. Our initial application, the CMI, uses this technology to guide the generation of new tissue in the medial meniscus of the knee.

Collagen is a multifunctional family of proteins with unique structural characteristics. To date, 19 different proteins can be classified as collagen, making collagen the most abundant protein in the human body. Among the various collagens, type I collagen is the most abundant and is the major constituent of bone, skin, and tendon.

The structure of animal type I collagen is highly similar to the structure of human type I collagen. This finding is supported by data from our current U.S. clinical trial. Based on the important functions of type I collagen in the body and the biocompatibility of animal type I collagen, this material has become increasingly popular as a biomaterial for clinical applications, particularly in the repair and generation of new tissue.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. For further discussion of our accounting policies see Note 1 “Summary of Significant Accounting Policies” of the Notes to Condensed Consolidated Financial Statements.

Results of Operations

Three and Six Months Ended June 30, 2004 Compared to Three and Six Months Ended June 30, 2003

REVENUE. The Company’s revenue for the three months ended June 30, 2004 was $159 compared with $29 for the same period in 2003, an increase of approximately $130 or 448%. Revenue for the six months ended June 30, 2004 was $266 compared with $211 for the same period in 2003, an increase of approximately $55 or 26%. These increases result from higher product sales to our distributors and related royalties.

CMI sales were $57 for the three months ended June 30, 2004 compared with $0 for the same period in 2003, an increase of $57 or 100%, due to the higher number of CMI units ordered by and therefore shipped to Centerpulse. Unit shipments of the CMI during the three months ended June 30, 2004 were 113 compared with 0 units shipped in the same period in 2003, an increase of 113 units, or 100%. CMI sales were $57 for the six months ended June 30, 2004 compared with $68 for the same period in 2003, a decrease of $11 or 16%, due to the lower number of CMI units ordered by and therefore shipped to Centerpulse. Unit shipments of the CMI during the six months ended June 30, 2004 were 113 compared with 139 units shipped in the same period in 2003, a decrease of 26 units, or 19%. Shipments of the CMI, and therefore revenue to the Company have been historically inconsistent. Effective April 17, 2004, we elected to convert our distribution agreement with Centerpulse to non-exclusive and continue to discuss with them potential future distribution relationships.

SharpShooter sales in the three months ended June 30, 2004 approximated $89 compared with $24 for the same period in 2003, a net increase of $65 or 271%. SharpShooter sales to Centerpulse for the three months ended June 30, 2004 were $21 compared to $23 for the same period in 2003, a decrease of $2 or 9%. This decrease was offset by the increase in SharpShooter sales to Linvatec, ReGen’s primary distributor for the SharpShooter. SharpShooter sales to Linvatec for the three months ended June 30, 2004 were $68 compared to $1 for the same period in 2003, an increase of $67 or 6700%. SharpShooter sales to Linvatec accounted for approximately 77% of total SharpShooter sales for the three months ended June 30, 2004 and 5% for the three months ended June 30, 2003. SharpShooter sales were $184 for the six months ended June 30, 2004 compared with $130 for the same period in 2003 an increase of $54, or 42%. SharpShooter sales to Centerpulse for the six month period ended June 30, 2004 were $24 compared to $82 for the same period in 2003, a decrease of $58 or 71%. This decrease was offset by the increase in SharpShooter sales to Linvatec. SharpShooter sales to Linvatec for the six months ended June 30, 2004 were $160 compared to $48 for the same period in 2003, an increase of $112 or 233%. SharpShooter sales to Linvatec accounted for approximately 87% of total SharpShooter sales for the six months ended June 30, 2004 and 37% for the six months ended June 30, 2003.

Royalties received from Linvatec for the three months ended June 30, 2004 approximated $13 compared with $5 for the same period in 2003, an increase of $8 or 160%. Royalties received for the six months ended June 30, 2004 approximated $25 compared with $13 for the same period in, 2003 an increase of $12 or 92%.

In March and April 2003, Conmed, the parent company of Linvatec announced that it had completed the acquisition of Bionx Implants, Inc. (“Bionx”) and that it would be integrating the sale of the Bionx products with its orthopedic subsidiary, Linvatec. As part of this integration, Conmed announced that it would be reorganizing its 90 direct orthopedic sales representatives into 18 exclusive sales agent groups that would eventually manage 230 sales professionals in the U.S. While shipments of the SharpShooter products have been historically inconsistent, we believe that these corporate and operating organizational matters had affected activities at Linvatec, such that orders of our products throughout most of 2003 were negatively impacted. Linvatec’s sales of the SharpShooter increased sequentially by 46% in the third quarter of 2003, 40% in the fourth quarter of 2003, 8% in the first quarter 2004 and 7% in the second quarter 2004, suggesting that our sales and royalty revenue, driven by Linvatec sales, will continue to improve in 2004 if this trend continues.

COST OF GOODS SOLD. Cost of goods sold approximated $122 for the three months ended June 30, 2004 compared with $25 for the same period in 2003, an increase of $97, or 388%, directly correlated to the increase in sales, particularly sales of CMI, which have a higher relative per unit cost. For the three months ended June 30, 2004 and 2003, respectively, CMI costs accounted for $53 and approximately $0. For the three months ended June 30, 2004 and 2003, respectively, SharpShooter costs accounted for approximately $69 and $25. Cost of goods sold approximated $181 for the six months ended June 30, 2004 compared with $296 for the same period in 2003, a decrease of $115, or 39%, directly correlated to the decrease in CMI sales, which have a higher relative per unit cost. For the six months ended June 30, 2004 and 2003, respectively, CMI costs accounted for $53 and approximately $97. For the six months ended June 30, 2004 and 2003, respectively, SharpShooter costs accounted for approximately $128 and $199. At June 30, 2004, 38% of the units in inventory are valued at below the Company’s cost. Due to a high degree of fixed costs in the production process, and the early stage of market acceptance for its products, current sales and production volumes are not adequate to provide for per unit costs that are lower than the current market price for some of the Company’s products.

RESEARCH AND DEVELOPMENT. Research and development expenses for the three months ended June 30, 2004 approximated $919 compared with $737 for the same period in 2003, an increase of approximately $182, or 25%. Research and development expenses for the six months ended June 30, 2004 approximated $1,704 compared with $1,147 for the same period in 2003, an increase of approximately $557, or 49%. These increases result from (i) the higher proportion of CMI units produced for development and quality control purposes versus those produced for commercial resale during the three and six month periods ended June 30, 2004 as compared with the same periods in 2003, and (ii) increased development costs, primarily for consulting services, in connection with the Pre-market Approval submission for the CMI. Management expects these trends to continue through 2004, as we prepare our PMA for submission to the FDA. In early July 2004 the Company submitted the manufacturing module of the modular PMA for the CMI to the FDA, an important step toward a final decision from the FDA regarding approval of the CMI.

BUSINESS DEVELOPMENT, GENERAL AND ADMINISTRATIVE. Business development, general and administrative expenses approximated $813 for the three months ended June 30, 2004 compared with $695 for the same period in 2003, an increase of approximately $118, or 17%, resulting primarily from (i) an increase of approximately $169 in professional services including legal representation, accounting services and stock transfer and exchange services, (ii) an increase of approximately $4 in employee compensation, (iii) an increase of approximately $73 in printing cost related to security filings, (iv) an increase of approximately $25 in investor relations and (v) an offsetting decrease of approximately $158 related to expensed financing costs incurred in connection with the Series C financing that closed in September 2003. Business development, general and administrative expenses approximated $1,620 for the six months ended June 30, 2004 compared with $1,251 for the same period in 2003, an increase of approximately $369, or 29%, resulting primarily from (i) an increase of approximately $361 in professional services including legal representation, accounting services and stock transfer and exchange services, (ii) an increase of approximately $26 in employee compensation, (iii) an increase of approximately $73 in printing cost related to security filings, (iv) an increase of approximately $59 in investor relations and (v) an offsetting decrease of approximately $158 related to expensed financing costs incurred in connection with the Series C financing. Management expects these trends to continue through 2004.

COMPENSATION EXPENSE ASSOCIATED WITH STOCK OPTIONS AND WARRANTS. Compensation expense associated with stock options and warrants for the three months ended June 30, 2004 approximated $38, compared to $1 for the same period in 2003. Stock based compensation expense for the three months ended June 30, 2004 consisted of (i) $6 for non-employees and ii) $32 for employees. Compensation expense associated with stock options and warrants for the six months ended June 30, 2004 approximated $157, compared to $1 for the same period in 2003. Stock based compensation expense for the six months ended June 30, 2004 consisted of (i) $12 for non-employees and ii) $145 for employees.

NON-OPERATING INCOME (EXPENSE). Non-operating income (expense) consists of interest and other income, rental income, rental expense, interest expense and license fees. Interest and other income approximated $30 for the three months ended June 30, 2004 compared with $2 for the same period in 2003, an increase of approximately $28. Interest and other income approximated $39 for the six months ended June 30, 2004 compared with $7 for the same period in 2003, an increase of approximately $32. These increases are primarily related to higher balances of cash and cash equivalents during the respective periods in 2004. Net rental income, which is sub-lease rental revenue less rent and operating expenses related to the sub-leased portion of the Company’s Redwood City, CA facility, approximated $0 for the three months ended June 30, 2004 compared with $2 for the same period in 2003. Net rental income approximated $1 for the six months ended June 30, 2004 compared with $24 for the same period in 2003. Sub-lease rent was reduced pursuant to amendments to the sub-lease agreement, which became effective June 1, 2003. Interest expense for the three months ended June 30, 2004 approximated $31 compared with $27 for the same period in 2003, an increase of approximately $4. Interest expense for the six months ended June 30, 2004 approximated $60 compared with $63 for the same period in 2003, a decrease of approximately $3. The increase and decrease are primarily due to fluctuating interest rates.

Liquidity and Capital Resources

On April 19, 2004, the Company completed a private placement for 12,074,595 shares of restricted common stock at a price per share of $0.85 (the April Financing), resulting in proceeds net of issuance costs of approximately $9,866, which the Company has deposited into its money market account. The common stock sold in the private placement may be registered by the Company on one or more registration statements to be filed with the SEC, and will be subject to lock-up provisions for a period of 150 days after the completion of the private placement. On July 14, 2004, the Company filed a preliminary registration statement with the SEC on Form S-1 for registration of 47,624,409 common shares to be sold at the election of the selling stockholders. The shares being registered include common shares registered pursuant to the Registration Rights Agreements with the holders of Series A Stock and Series C Stock (issuable upon the conversion of certain shares of Series A Stock and Series C Stock) and the common shares issued pursuant to the April Financing. The Registration Statement was declared effective with the SEC on July 23, 2004.

Cash and cash equivalents were approximately $15,208 as of June 30, 2004 compared with approximately $8,323 as of December 31, 2003. The increase in cash and cash equivalents is primarily the net effect of cash used to support the normal operations of ReGen offset by net proceeds of $9,866 from the April Financing.

Cash used in operating activities of approximately $3,012 resulted from the net loss of approximately $3,416, adjusted to account for a net decrease in accounts receivables, inventory and other assets of approximately $13, a net increase in accounts payable, accrued expenses and other liabilities of $135, together with adjustments for non-cash items, depreciation, compensation and interest expense, totaling $256.

During the six months ended June 30, 2004, ReGen invested approximately $14 to purchase property and equipment including $4 pursuant to financing lease accounted for as a capital lease.

During the six months ended June 30, 2004 ReGen’s financing activities provided approximately $9,907, including approximately $31 in proceeds from the exercise of 69,930 common stock warrants, $13 in proceeds from the exercise of 80,000 common stock options and $9,866 in net proceeds from the April Financing, offset by $2 repayment of capital lease obligations.

Through June 30, 2004, the Company has incurred cumulative net operating losses of approximately $51,000 and used approximately $39,200 in cash for operating activities. ReGen anticipates that it will continue to incur net losses at least until ReGen receives FDA approval for its CMI product and is able to market the CMI product in the United States. Due primarily to incremental spending necessary for the preparation and submission of the Pre-market Approval Application (the “PMA”) for the CMI, cash required to support operating activities is expected to increase by approximately $2,000 in 2004 and is expected to further increase in future periods as the Company begins to incur additional expenses associated with the preparation for and launch of sales of the CMI product in the U.S., if approved by the FDA.

The Company anticipates that additional funds will be required to satisfy expenses associated with the preparations for and, if approved, the launch of, sales of the CMI in the U.S., and other marketing, distribution and product development related activities. Such additional funds may be obtained in the form of debt financing, equity financing, or both. While the Company has been successful in the past in obtaining the necessary capital to support its operations, there is no guarantee that the Company will be able to obtain additional equity capital under commercially reasonable terms and conditions, or at all. Based upon current cash reserves, net proceeds received from the April Financing, and planned spending rates, management believes the Company has adequate cash on hand to support ongoing operations through the expected date of the FDA decision regarding U.S. marketing of our CMI product in 2006.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

Cautionary Note Regarding Forward-Looking Statements

Statements in this filing, which are not historical facts, are forward-looking statements under provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve risks and uncertainties. Such statements are based on the current expectations and beliefs of the managements of ReGen and RBio and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of the Form S-1 declared effective July 23, 2004. We wish to caution readers that the following important factors, among others, in some cases have affected, and in the future could affect our actual results and could cause our actual results in fiscal 2004 and beyond to differ materially from those expressed in any forward-looking statements made by us or on our behalf.

Important factors that could cause actual results to differ materially include but are not limited to our ability to complete the Collagen Meniscus Implant, or CMI, clinical trial and obtain U.S. Food and Drug Administration, or FDA, approval, our ability to obtain additional financing, the ability of our distribution partners to effectively market and sell our products, our ability to procure product components and effectively produce products for resale, our ability to control production quantities and inventory in order to avoid unanticipated costs such as outdated inventory, the timely collection of our accounts receivable, our ability to attract and retain key employees, our ability to timely develop new products and enhance existing products, the occurrence of certain operating hazards and uninsured risks, our ability to protect proprietary information and to obtain necessary licenses on commercially reasonable terms, the impact of governmental regulations, changes in technology, marketing risks, our ability to be listed on a national securities exchange or quotation system, our ability to adapt to economic, political and regulatory conditions affecting the healthcare industry and other unforeseen events that may impact our business.

Our quarterly revenues and operating results have varied significantly in the past and are likely to vary from quarter to quarter in the future.

Quarterly revenues and operating results may fluctuate as a result of a variety of factors, including the ability of our distribution partners to market and sell our products, variable customer demand for our products and services, our investments in research and development or other corporate resources, our ability to effectively and consistently manufacture our products, and avoid costs associated with the recall of defective or potentially defective products, the ability of our vendors to effectively and timely deliver necessary materials and product components, acquisitions of other companies or assets, the timing of new product introductions, changes in distribution channels, sales and marketing promotional activities and trade shows and general economic conditions. Further, due to the relatively fixed nature of most of our costs, which primarily include personnel, facilities and related costs, any unanticipated shortfall in revenue in any fiscal quarter would have an adverse effect on our results of operations in that quarter. Accordingly, our operating results for any particular quarterly period may not necessarily be indicative of results for future periods.

Our filings with the SEC are available to the public from commercial document retrieval services and at the Web site maintained by the SEC at http://www.sec.gov.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

For information regarding ReGen’s exposure to certain market risks, see Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2003. Except as described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, there have been no significant changes in our financial instrument portfolio or market risk exposure since December 31, 2003.

Item 4. Controls and Procedures

We maintain “disclosure controls and procedures” within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures (“Disclosure Controls”), are designed to ensure that information required to be disclosed by the Company in the reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating and implementing possible controls and procedures.

Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this Quarterly Report on Form 10-Q, we evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer. Immediately following the Signatures section of this Quarterly Report on Form 10-Q are certifications of our Chief Executive Officer and Chief Financial Officer, which are required in accordance with Rule 13a-14 of the Exchange Act. This Controls and Procedures section includes the information concerning the controls evaluation referred to in the certifications and it should be read in conjunction with the certifications for a more complete understanding of the topics presented. Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the date of their evaluation, our Disclosure Controls and Procedures were effective to ensure that material information is made known to management, including our Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.

Changes in Internal Control Over Financial Reporting. There has been no change in the Company’s internal control over financial reporting that occurred during the Company’s second fiscal quarter of 2004 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II

Item 1. Legal Proceedings

We are a defendant or party from time to time in lawsuits incidental to our business. We are not currently subject to any material legal proceedings.

Item 2. Changes in Securities and Use of Proceeds (dollars in thousands, except per share data)

On April 19, 2004, the Company completed a private placement for 12,074,595 shares of restricted common stock at a price per share of $0.85, resulting in proceeds net of issuance costs of approximately $9,866 (the “April Financing”). The common stock sold in the private placement may be registered by the Company on one or more registration statements to be filed with the SEC, and will be subject to lock-up provisions for a period of 150 days after the completion of the private placement. All of these shares were issued in reliance upon an exemption from the registration requirements of the federal securities laws pursuant to Section 4(2) of the Securities Act because the shares were only offered to accredited investors.

Item 3. Defaults upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

The 2004 annual meeting of stockholders was held on May 25 2004. The matters on which the stockholders voted, in person or by proxy, were: (i) to elect six directors to serve until the Company’s next annual meeting of stockholders and until their successors are duly elected and qualified; (ii) to approve a one for eight reverse stock split of all of ReGen’s issued and outstanding Common Stock, subject to the authority of the Board; (iii) to approve the proposal to amend our Employee Stock Option Plan to increase the number of shares reserved for issuance under the Employee Stock Option Plan by 3,000,000 shares from 6,450,000 to 9,450,000 shares; (iv) to approve the proposal to amend our Non-Employee Director Stock Option Plan to increase the number of shares reserved for issuance under the Non-Employee Director Stock Option Plan by 1,000,000 shares from 1,500,000 to 2,500,000 shares; and (v) to ratify the appointment of Ernst & Young LLP as our independent accountants for the current fiscal year.

The results of the voting are shown below:

Election of directors:


Name of	Number of		Number of
Nominee	Votes For		Votes Withheld
Gerald E. Bisbee, Jr., Ph.D.		53,553,387		10,603
Abhi Acharya, Ph.D.		53,553,387		10,603
Alan Baldwin		53,553,387		10,603
Richard Fritschi		53,553,387		10,603
Robert G. McNeil, Ph.D.		53,553,387		10,603
Richard J. Steadman, M.D.		53,553,387		10,603

Approval of a one for eight reverse stock split of all of ReGen’s issued and outstanding Common Stock, subject to the authority of the Board:

Number of

Votes

Votes For

Votes Against

Abstaining

Not Voted

53,272,920

288,083

2,987

-0-

Approval of the proposal to amend our Employee Stock Option Plan:

Number of

Votes For

Votes Against

Votes Abstaining

Not Voted

46,847,287

611,166

33,899

6,071,638

Approval of the proposal to amend our Non-Employee Director Stock Option Plan:

Number of

Votes

Votes For

Votes Against

Abstaining

Not Voted

46,763,390

682,463

46,499

6,071,638

Ratification of the selection of Ernst &Young LLP as independent auditors:

Number of

Votes

Votes For

Votes Against

Abstaining

Not Voted

53,351,267

211,273

1,450

-0-

Item 5. Other Information

None.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits.

The following Exhibits are filed herewith and made a part hereof:


Number		Description
2.1		Agreement and Plan of Merger by and among ReGen Biologics, Inc., Aros Corporation and Aros Acquisition Corporation dated as of June 7, 2002(1)

2.2		Agreement and Plan of Merger among the Company, NHA Acquisition Corporation, National Health Advisors, Ltd., Scott A. Mason and Donald W. Seymour dated as of June 2, 1997(5)

2.3		Agreement and Plan of Merger among the Company and MetaContent, Inc. dated as of March 21, 2001(2)

2.4		Asset Purchase Agreement between Cerner Corporation and the Company dated as of April 7, 2001(3)

2.5		Amendment No. 1 to Asset Purchase Agreement by and between Cerner Corporation and the Company dated as of June 11, 2001(3)

3.1		Amended and Restated Certificate of Incorporation(5)

3.2		Certificate of Amendment to the Certificate of Incorporation(6)

3.3		Amended and Restated By-Laws(4)

3.4		Certificate of Amendment of the Amended and Restated Certificate of Incorporation(17)

4.1		Specimen Common Stock Certificate(7)

4.2		Rights Agreement between the Company and First Chicago Trust Company of New York, dated as of May 6, 1997(9)

4.3		ReGen Biologics, Inc. Employee Stock Option Plan, Amended and Restated Effective January 31, 2003(12)

4.4		ReGen Biologics, Inc. Non-Employee Director Stock Option Plan, Amended and Restated Effective January 31, 2003(12)

4.5		Registration Rights Agreement between the Company and the Investors listed therein(8)

4.6		Registration Agreement between the Company and Certain Stockholders, dated December 28, 1995(18)

4.7		Amendment No. 1 to Rights Agreement between the Company and EquiServe Trust Company, N.A. dated as of June 7, 2002(10)

4.8		Nonqualified Stock Option Agreement between the Company and The Cleveland Clinic Foundation, dated August 19, 1994(18)

4.9		Registration Agreement between the Company and each of Iowa Health Centers, P.C. d/b/a Iowa Heart Center, P.C., Mercy Hospital Medical Center, Mark A. Tannenbaum, M.D. and Iowa Heart Institute dated January 7, 1997(14)

4.10		Nonqualified Stock Option Agreements between the Company and each of Iowa Health Centers, P.C. d/b/a Iowa Heart Center, P.C., Mercy Hospital Medical Center and Mark A. Tannenbaum, M.D., dated January 7, 1997(19)

4.11		Form of Nonqualified Director Stock Option Agreement(11)

4.12		Stockholders’ Agreement by and among the several stockholders named therein, dated as of June 21, 2002(15)

4.13		Amendment to Stockholders’ Agreement by and among Allen & Company Incorporated and the several stockholders named therein, dated as of December 4, 2002(16)

4.14		ReGen Biologics, Inc. Non-Employee Director Supplemental Stock Option Plan Amended and Restated Effective January 31, 2003(21)

4.15		Common Stock Registration Rights Agreement by and among ReGen Biologics, Inc., and the stockholders named therein, dated as of April 19, 2004(22)

10.1		Employment agreement by and between Gerald E. Bisbee, Jr., Ph. D. and ReGen Biologics, Inc. dated September 22, 1998 and amended


		September 12, 2000(13)

10.2		Form of Indemnification Agreement(4)

10.3		Distributorship Agreement by and between ReGen Biologics, Inc. and Sulzer Orthopedics AG dated February 16, 1996(20)

10.4		Employment agreement by and between Brion D. Umidi and ReGen Biologics, Inc. dated March 23, 2004(20)

10.5		Amendment to Distributorship Agreement by and between ReGen Biologics, Inc. and Sulzer Orthopedics AG dated January 18, 2002(20)

10.6		License Agreement by and between ReGen Biologics, Inc. and Linvatec Corporation dated April 7, 2000(20)

10.7		Credit Agreement by and between ReGen Biologics, Inc. and Sulzer Medica USA Holding Company dated March 14, 2000(20)

10.8		Agreement by and among Sulzer Medica USA Holding Co., Sulzer Biologics Inc. Sulzer Orthopedics Ltd. and ReGen Biologics, Inc. dated February 20, 2001(20)

10.9		Assignment and Royalty Agreement by and among ReGen Biologics, Inc. Modified Polymer Components, Inc. and Dr. J. Richard Steadman dated April 9, 1997(20)

10.10		Exclusive License Agreement by and between ReGen Biologics, Inc. and Dr. Shu-Tung Li dated August 24, 1995(20)

10.11		First Amendment to Employment Agreement by and between Gerald E. Bisbee, Jr., Ph. D. and ReGen Biologics, Inc. dated March 23, 2004(20)

10.12		Common Stock Purchase Agreement by and among ReGen Biologics, Inc., and the Individuals named therein, dated as of April 19, 2004(22)

31.1		Section 302 Certification from Gerald E. Bisbee, Jr., dated August 12, 2004(23)

31.2		Section 302 Certification from Brion Umidi, dated August 12, 2004(23)

32.1		Section 906 Certification from Gerald E. Bisbee, Jr., dated August 12, 2004(23)

32.2		Section 906 Certification from Brion Umidi, dated August 12, 2004(23)


(1)		Incorporated herein by reference to the Company’s Report on Form 10-Q for the quarter ended June 30, 2002 (File No. 000-20805).

(2)		Incorporated herein by reference to the Company’s Report on Form 10-Q/A for the quarter ended March 31, 2001 (File No. 000-20805).

(3)		Incorporated herein by reference to the Company’s Report on Form 8-K filed on July 18, 2001 (File No. 000-20805).

(4)		Incorporated herein by reference to the Company’s Report on Form 8-K filed on March 17, 2004 (File No. 000-20805).

(5)		Incorporated herein by reference to the Company’s Report on Form 10-Q for the quarter ended June 30, 1997 (File No. 000-20805).

(6)		Incorporated herein by reference to the Company’s Report on Form 10-Q for the quarter ended June 30, 2001 (File No. 000-20805).

(7)		Incorporated herein by reference to the Company’s Registration Statement on Form S-3, filed on November 19, 2003 (File No. 333-110605).

(8)		Incorporated herein by reference to the Company’s Report on Form 8-K, filed on September 25, 2003 (File No. 000-20805).

(9)		Incorporated herein by reference to the Company’s Report on Form 8-K filed on June 4, 1997 (File No. 000-20805).

(10)		Incorporated herein by reference to the Company’s Report on Form 10-Q for the quarter ended June 30, 2002 (File No. 000-20805).

(11)		Incorporated herein by reference to the Company’s Report on Form 10-K for the year ended December 31, 1997 (File No. 000-20805).

(12)		Incorporated herein by reference to the Company’s Proxy Statement on Schedule 14A filed on April 14, 2003 (File No. 000-20805).


(13)		Incorporated herein by reference to the Company’s Report on Form 8-K/A, filed on September 4, 2002 (File No. 000-20805).

(14)		Incorporated herein by reference to the Company’s Current Report on Form 8-K filed on January 14, 1997 (File No. 000-20805).

(15)		Incorporated herein by reference to the Company’s Report on Form SC 13D filed on March 24, 2003 (File No. 005-49089).

(16)		Incorporated herein by reference to the Company’s Report on Form SC 13D/A filed on October 3, 2003 (File No. 005-49089).

(17)		Incorporated herein by reference to the Company’s Report on Form 8-K, filed on January 6, 2003 (File No. 000-20805).

(18)		Incorporated herein by reference to the Company’s Registration Statement on Form S-1, filed on June 4, 1996 (File No. 333-04106).

(19)		Incorporated herein by reference to the Company’s Report on Form 10-Q for the quarter ended March 31, 1997 (File No. 000-20805).

(20)		Incorporated herein by reference to the Company’s Report on Form 10-K for the year ended December 31, 2003 (File No. 000-20805)

(21)		Incorporated herein by reference to the Company’s Registration Statement on Form S-1/A, filed on January 14, 2004 (File No. 333-110605).

(22)		Incorporated herein by reference to the Company’s Registration Statement on Form S-1, filed on April 26, 2004 (File No. 33-114867)

(23)		Included with this filing.

(b) Reports on Form 8-K.

A Current Report on Form 8-K was filed on April 23, 2004 to announce that on April 19, 2004 the Company completed a $10,263,402 private equity placement with the sale of common stock to certain institutional and other accredited investors.

A Current Report on Form 8-K was filed on June 10, 2004 to announce the appointment of William R. Timken to the board of directors and the Audit Committee of the board of directors.

A Current Report on Form 8-K was filed on July 29, 2004 to announce the submission of the Company’s manufacturing module of its PMA for the CMI product to the FDA.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents


PART I — Financial Information
Item 1.		Financial Statements
		Condensed Consolidated Balance Sheets at June 30, 2004 (unaudited) and December 31, 2003
		Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2004 (unaudited) and 2003 (unaudited), the Six Months Ended June 30, 2004 (unaudited) and 2003 (unaudited) and the Period from December 21, 1989 to June 30, 2004 (unaudited)
		Consolidated Statement of Changes in Stockholders’ Equity (Deficit) and Series A & Series C Redeemable Convertible Preferred Stock for the Period from December 21, 1989 (inception) to June 30, 2004 (unaudited)
		Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2004 (unaudited) and 2003 (unaudited) and the Period from December 21, 1989 (inception) to June 30, 2004 (unaudited)
		Notes to Condensed Consolidated Financial Statements (unaudited)
Item 2.		Management’s Discussion and Analysis of Financial Conditions and Results of Operations
Item 3.		Quantitative and Qualitative Disclosures about Market Risk
Item 4.		Controls and Procedures
PART II — Other Information
Item 1.		Legal Proceedings
Item 2.		Changes in Securities and Use of Proceeds
Item 3.		Defaults upon Senior Securities
Item 4.		Submission of Matters to a Vote of Security Holders
Item 5.		Other Information
Item 6.		Exhibits and Reports on Form 8-K
Signatures
Certifications
Exhibit 31.1
EXhibit 31.2
Exhibit 32.1
Exhibit 32.2

•		Substantial growth of new tissue in the meniscus, which does not otherwise re-grow after removal in a partial meniscectomy;

•		Significantly greater return to a more active lifestyle than those patients’ receiving only a partial meniscectomy; and

•		A highly correlated relationship between the patients pain and function, and their degree of return to pre-injury activity, e.g. CMI patients experience an approximately equal level of pain as do the patients in the control group who received only a partial meniscectomy, but do so at a significantly higher return to pre-injury activity levels.

•		Obtaining FDA approval of the CMI;

•		Developing our distribution and marketing capabilities for the CMI both in the U.S. and throughout certain other countries;

•		Launching the CMI in the U.S.; and

•		Conducting further research on select product opportunities within our research and development pipeline to determine whether to pursue further development of these opportunities.